The introduction of immunotherapy, either as monotherapy or in combination with tyrosine kinase inhibitors (TKIs), has profoundly reshaped the first-line treatment of metastatic renal cell carcinoma. Nevertheless, most patients eventually experience disease progression, highlighting the unmet clinical need for effective therapeutic strategies in the post-immunotherapy setting. Cabozantinib, a multikinase TKI targeting VEGFR, MET, and AXL, represents one of the most established treatment options in this context. This mini-review summarizes the biological rationale, key clinical evidence, and the most recent data presented at major international congresses, with a specific focus on the positioning of cabozantinib after failure of immunotherapy-based regimens or immune-TKI combinations.
Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma / Catalano, M., Venturini, J., Vascotto, I.A., Sthembari, K., Mancini, S., Pratesi, L., Paulet, A., Mela, M.M., Rossi, V., Pillozzi, S., Antonuzzo, L., Roviello, G.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - ELETTRONICO. - 223:(2026), pp. 105334.1-105334.6. [10.1016/j.critrevonc.2026.105334]
Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma
Catalano, Martina;Venturini, Jacopo;Vascotto, Ismaela Anna;Mancini, Silvia;Pratesi, Luca;Paulet, Alexandra;Rossi, Virginia;Pillozzi, Serena;Antonuzzo, Lorenzo;Roviello, Giandomenico
2026
Abstract
The introduction of immunotherapy, either as monotherapy or in combination with tyrosine kinase inhibitors (TKIs), has profoundly reshaped the first-line treatment of metastatic renal cell carcinoma. Nevertheless, most patients eventually experience disease progression, highlighting the unmet clinical need for effective therapeutic strategies in the post-immunotherapy setting. Cabozantinib, a multikinase TKI targeting VEGFR, MET, and AXL, represents one of the most established treatment options in this context. This mini-review summarizes the biological rationale, key clinical evidence, and the most recent data presented at major international congresses, with a specific focus on the positioning of cabozantinib after failure of immunotherapy-based regimens or immune-TKI combinations.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1040842826002210-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
450.46 kB
Formato
Adobe PDF
|
450.46 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



